$ALVO News
Last published 4h ago
- 4h agoALVOAlvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business UpdateGlobeNewswireREYKJAVIK, ICELAND (November 11, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company specializing in...
- 4h agoALVOAlvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business UpdateGlobeNewswireREYKJAVIK, Iceland, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (“Alvotech” or the “Company”), a global biotechnology company...
- 1w agoALVOAlvotech to Present at Upcoming Investor Conferences in NovemberGlobeNewswireREYKJAVIK, Iceland, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,
- 2w agoALVOAlvotech to Report Financial Results for the Nine-Month Period to September 30, 2026GlobeNewswireREYKJAVIK, Iceland, Oct. 28, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines
- 3w agoALVOAlvotech Receives FDA Approval for New SIMLANDI® Manufacturing Process That More Than Doubles Output Per BatchGlobeNewswireREYKJAVIK, Iceland and LONDON, Oct. 20, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients
- 4w agoALVOAlvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mgGlobeNewswireAVT29 submitted to the European Medicines Agency as a line extension to the existing marketing authorization for Mynzepli® (aflibercept 2 mg) High-dose aflibercept offers the potential to reduce treatment frequency for
- 1mo agoALVOAlvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supplyGlobeNewswireCollaboration covers multiple biosimilar products to be manufactured at LOTTE Biologics’ Syracuse facility in New York Strategic long-term partnership to increase Alvotech’s global manufacturing capacity and support
- 1mo agoALVOMorgan Stanley 24th Annual Global Healthcare Conference - ALVOTECHEarnings Call TranscriptsSo, thank you for joining this session of the Morgan Stanley Global Healthcare Conference. I am Thibaut Woutran. I am part of the European Equity Research Team based in London. Before we start the session, I need to refe
- 2mo agoALVOAlvotech Announces FDA Acceptance for Review of Biologics License Application for AVT80, Expanding Proposed Biosimilar Program for Entyvio® to Subcutaneous PresentationsGlobeNewswireREYKJAVIK, Iceland, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,
- 2mo agoALVOAlvotech to present at upcoming investor conferences in SeptemberGlobeNewswireREYKJAVIK, Iceland, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,
- 2mo agoALVOAlvotech Announces Licensing and Commercialization Agreement with Lotus Pharmaceutical for proposed biosimilars to durvalumab and emicizumab in the U.S. and Selected Asian MarketsGlobeNewswireREYKJAVIK, Iceland, Aug. 21, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,
- 2mo agoALVOAlvotech Q2 2026 Earnings Conference Call - ALVOTECHEarnings Call TranscriptsThank you, and welcome to our listeners. Yesterday evening, the company issued a press release announcing our financial results for the first half of 2026. Material accompanying today's earnings call, including a supplem
- 2mo agoALVOAlvotech Announces Financial Results for the First Half of 2026 and Provides a Business UpdateGlobeNewswireREYKJAVIK, Iceland, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of
- 3mo agoALVOAlvotech to Report Financial Results for H1 2026GlobeNewswireREYKJAVIK, Iceland, Aug. 10, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines
- 3mo agoALVOAlvotech announces successful closure of FDA inspection of manufacturing facilityGlobeNewswireREYKJAVIK, Iceland, July 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines
- 4mo agoALVOAlvotech Q1 2026 Earnings Conference CallALVOTECHEarnings Call Transcriptswelcome to our listeners yesterday evening the company issued a press release announcing our financial results for the first quarter of 2026. material accompanying today's earnings call including a supplemental earnings
- 4mo agoALVOAlvotech further strengthens liquidity by securing term loan facility of $75 millionGlobeNewswire— $75 million additional term loan facility maturing December 31, 2027, led by GoldenTree Asset Management — Follows recent $165m equity raise strengthening cash position — Including equity financing and undrawn loan
- 4mo agoALVOAlvotech Announces Closing of Public Offering and Full Exercise by Underwriters of Option to Purchase Additional Shares, Raising an Aggregate of $165 Million with Concurrent Private PlacementGlobeNewswireREYKJAVIK, Iceland, June 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar
- 4mo agoALVOAlvotech Announces Pricing of $152 Million Public Offering of Ordinary Shares and Concurrent Private PlacementGlobeNewswireREYKJAVIK, Iceland , June 16, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) ("Alvotech" or the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar
- 5mo agoALVOGoldman Sachs 47th Annual Global Healthcare Conference - ALVOTECHEarnings Call TranscriptsGreat. Well, good morning, everyone, and thank you for joining us. My name is Matt De La Torre, and I'm a biopharma analyst here at Goldman Sachs, and we're very pleased to continue the next session this morning with Alv
- 5mo agoALVOAlvotech announces FDA acceptance of Biologics License Application for AVT16, a proposed interchangeable biosimilar to Entyvio®GlobeNewswireREYKJAVIK, Iceland, June 08, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,
- 5mo agoALVOJEFFERIES GLOBAL HEALTHCARE CONFERENCE IN NEW YORK - ALVOTECHEarnings Call TranscriptsGood morning, and welcome to the Jeffries Global Healthcare Conference in New York. My name is Marco Baruzzi from the Jefferies Investment Banking team, and it's my great pleasure to introduce you to Robert Westman, foun
- 5mo agoALVOAlvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®GlobeNewswireREYKJAVIK, Iceland, June 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide,
- 5mo agoALVOMain Results of 2026 Annual and Extraordinary General MeetingGlobeNewswireREYKJAVÍK, Iceland and LUXEMBOURG, June 03, 2026 (GLOBE NEWSWIRE) -- The 2026 Annual and Extraordinary General Meeting of Alvotech (the "2026 AGM") was held on June 3, 2026, at Arendt House, 41A Avenue John F.
- 5mo agoALVOAlvotech to present at upcoming investor conferences in JuneGlobeNewswireREYKJAVIK, Iceland, June 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for
- 6mo agoALVO2026 GLOBAL HEALTHCARE CONFERENCE - ALVOTECHEarnings Call TranscriptsAll right, everybody, we're going to get going here with our next company presenter at the B of A Annual Healthcare Conference, Jason Gerberry, Pharma and Biotech Analyst. Pleased to be introducing Alvatech and Balaji Pr
- 6mo agoALVOAlvotech Announces Completion of FDA Surveillance Inspection at Reykjavik FacilityGlobeNewswire- Company remains on track for BLA resubmissions in the second quarter REYKJAVIK, Iceland, May 11, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)), a global biotechnology company specializing in the
- 6mo agoALVOAlvotech Q1 2026 Financial ResultsGlobeNewswireREYKJAVIK, Iceland, May 06, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB)) Financial Highlights A supplemental long‑form earnings release providing additional operational
- 6mo agoALVOAlvotech Announces a Change in its Executive TeamGlobeNewswireREYKJAVIK, Iceland, April 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, the "Company")), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide,
- 6mo agoALVOAlvotech to Report Financial Results for the First Quarter of 2026GlobeNewswireREYKJAVIK, Iceland, April 24, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO, ALVO-SDB)) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for
- 7mo agoALVOAlvotech Files Annual Report with the SECGlobeNewswireREYKJAVIK, Iceland, March 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO) (the "Company") has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with the U.S. Securities and Exchange Commission
- 7mo agoALVOAlvotech Q4 2025 and Full Year 2025 Earnings Conference CallALVOTECHEarnings Call TranscriptsThank you, and welcome to our listeners. Yesterday evening, the company issued a press release announcing our financial results for the full year and fourth quarter of 2025. Material accompanying today's earnings call wa
- 8mo agoALVOAlvotech to Report Fourth Quarter and Full Year 2025 Financial ResultsGlobeNewswireREYKJAVIK, Iceland, March 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO) (the "Company"), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients
- 9mo agoALVOAlvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®GlobeNewswireThe study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all its primary endpoints REYKJAVIK, Iceland, Feb. 05, 2026
- 9mo agoALVOAlvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidatesGlobeNewswireREYKJAVIK, Iceland, Feb. 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today
- 9mo agoALVOAlvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mgGlobeNewswireREYKJAVIK, Iceland, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today
- 10mo agoALVOAlvotech Secures Term Loan Facility of USD 100 MillionGlobeNewswireUSD 100 million senior term loan facility with a 2-year maturityStrengthens liquidity to support execution across Alvotech's R&D pipeline and global product launches through 2026Led by GoldenTree Asset Management
- 10mo agoALVOAlvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®GlobeNewswireREYKJAVIK, Iceland and TEL AVIV, Israel and PARSIPPANY, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines
- 11mo agoALVOAlvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic AreaGlobeNewswireREYKJAVIK, Iceland, Nov. 24, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced
- 11mo agoALVOAlvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)GlobeNewswireREYKJAVIK, Iceland and LONDON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and
- 11mo agoALVOALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLPBusiness WireThe law firm of Kirby McInerney LLP reminds investors its investigation on behalf of Alvotech ("Alvotech" or the "Company") (NASDAQ:ALVO) investors concerning the Company's and/or members of its senior management's
- 12mo agoALVOAlvotech Q3 2025 Earnings Conference Call - ALVOTECHEarnings Call Transcriptswelcome to our listeners. Yesterday evening, the company issued a press release announcing our financial results for the first nine months and third quarter of 2025. A presentation accompanying today's earnings call was
- 12mo agoALVOAlvotech Reports Results for the First Nine Months of 2025 and Provides a Business UpdateGlobeNewswireTotal revenues in the first nine months of the year were $420 million, a 24% increase from the same period last year Product and service revenue increased by 85%, to $237 million in the first nine months compared to the
- 1y agoALVOUK High Court Rules in Favor of Alvotech Paving Way for Manufacture and Market Entry of AVT06, biosimilar to Eylea® (aflibercept)GlobeNewswireREYKJAVIK, Iceland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today the
- 1y agoALVOAlvotech and Advanz Pharma Receive Marketing Authorisations for Gobivaz®, a Biosimilar to Simponi® (golimumab), from the MHRAGlobeNewswireREYKJAVIK, Iceland and LONDON, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and
- 1y agoALVOAlvotech INVESTIGATION: Kirby McInerney LLP Announces Investigation Into Potential Securities Fraud on behalf of Investors (ALVO)GlobeNewswireNEW YORK, Nov. 04, 2025 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Alvotech ("Alvotech" or the "Company") (NASDAQ:ALVO). The investigation concerns whether the
- 1y agoALVOAlvotech Announces Webcast on November 13, 2025 to Report Financial Results for the First Nine Months of 2025 and Provide a Business UpdateGlobeNewswireREYKJAVIK, Iceland, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients worldwide, announced today that
- 1y agoALVOAlvotech Provides Update on the Status of U.S. Biologics License Application for AVT05GlobeNewswireREYKJAVIK, Iceland, Nov. 02, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, announced today
- 1y agoALVOAlvotech Announces Changes in Global Business Development and Commercial Operations TeamGlobeNewswireREYKJAVIK, Iceland, Oct. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ:ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced
- 1y agoALVOAMRXKashiv Biosciences Announces Submission of Biologics License Application to U.S. FDA and Acceptance of Market Authorization Application by European Medicines Agency for ADL-018, a Proposed Biosimilar to XOLAIR® (omalizumab)Business WireKashiv Biosciences has submitted its Biologics License Applications (BLA) for ADL-018 as a biosimilar to reference product XOLAIR® (omalizumab) to the U.S. Food and Drug Administration (FDA) The Marketing